Project description DEENESFRITPL A more effective and safer ablation strategy for treating atrial fibrillation Atrial fibrillation (AF) is the most common cardiac arrhythmia and is usually treated with catheter ablation, using either radio-frequency or cryoablation, scarring the tissue in the heart responsible for sending faulty electrical signals. This approach has a limited success rate with non-durable results and requires skills and expertise. The scope of the EU-funded BEAT AF project is to develop an alternative ablation strategy for a more long-lasting effect on AF symptoms. BEAT AF will employ pulsed electric field (PEF) energy which works by creating nanoscale pores in cell membranes. Researchers will undertake clinical trials to validate the effectiveness and superiority of PEF ablation compared to ablation using radiofrequency or cryothermal energy. Show the project objective Hide the project objective Objective Atrial fibrillation (AF), the most common arrhythmia, accounts for 1/3rd of Cardiovascular expenses, with over 10 millions affected in Europe. In addition to significant impact on quality of life, AF exposes patients to stroke, heart failure, dementia and death. AF is the most commonly ablated arrhythmia. The Pulmonary Vein Isolation (PVI) is the cornerstone of AF ablation, preventing recurrences, especially in patients with paroxysmal AF. Catheter ablation of AF uses either radio-frequency (RF) or cryothermal (cryo) energy. Common to these thermal energy sources is their reliance on time-dependent conductive heating/cooling and the fact that these modalities ablate all tissue types indiscriminately. The ablation procedure remains long, requires skills and expertise, and has a limited success rate, mostly because of non-durable lesions after PVI implying frequent redo procedures. And these energies are associated with rare but severe complications due to their thermal nature. The goal of BEAT AF is to disrupt AF ablation by achieving durable PVI with permanent, coalescent and transmural ablation lesions using Pulsed Electric Field (PEF) energy. PEF is non-thermal and creates nanoscale pores in cell membranes. Cardiac cells are highly sensitive to PEF unlike phrenic and oesophageal cells. BEAT AF aims to demonstrate that PEF ablation is faster, more effective and safer (tissue selectivity) than RF or cryo ablation. For this purpose, two distinct randomized clinical trials will be conducted: 1) to provide first comparative evidence of the superiority of PEF over RF on the rate of 1-year recurrence for paroxysmal AF, and 2) to provide first evidence of potential efficacy of PEF on the rate of 1-year clinical recurrence for persistent AF. The BEAT AF consortium gathers 9 European renowned clinical centres (France, Czech Republic, Germany, Austria, Belgium) to set the ground for large trials and contribute to decrease the huge burden of AF in Europe. Fields of science engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsradio technologyradio frequencymedical and health sciencesclinical medicinecardiologycardiovascular diseasescardiac arrhythmiamedical and health sciencesbasic medicineneurologydementiamedical and health sciencesbasic medicineneurologystrokesocial sciencespolitical sciencesgovernment systems Keywords Cardiovascular diseases Atrial fibrillation pulmonary vein isolation catheter ablation radiofrequency cryothermy pulsed electric field Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SC1-BHC-08-2020 - New interventions for Non-Communicable Diseases Call for proposal H2020-SC1-BHC-2018-2020 See other projects for this call Sub call H2020-SC1-2020-Two-Stage-RTD Funding Scheme RIA - Research and Innovation action Coordinator UNIVERSITE DE BORDEAUX Net EU contribution € 1 474 812,50 Address Place pey berland 35 33000 Bordeaux France See on map Region Nouvelle-Aquitaine Aquitaine Gironde Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Participants (8) Sort alphabetically Sort by Net EU contribution Expand all Collapse all RHON-KLINIKUM AG Germany Net EU contribution € 216 250,00 Address Salzburger leite 1 97616 Bad neustadt a d saale See on map Region Bayern Unterfranken Rhön-Grabfeld Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 CHU HOPITAUX DE BORDEAUX France Net EU contribution € 1 512 043,00 Address Rue dubernat 12 33404 Talence See on map Region Nouvelle-Aquitaine Aquitaine Gironde Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Institut klinické a experimentální mediciny Czechia Net EU contribution € 214 062,50 Address Videnska 1958/9 14021 Prague 4 See on map Region Česko Praha Hlavní město Praha Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 MEDIZINISCHE UNIVERSITAT GRAZ Austria Net EU contribution € 263 875,00 Address Neue stiftingtalstrasse 6 8010 Graz See on map Region Südösterreich Steiermark Graz Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 ALGEMEEN ZIEKENHUIS SINT-JAN BRUGGE-OOSTENDE AUTONOME VERZORGINSINSTELLING Belgium Net EU contribution € 211 950,00 Address Ruddershove 10 8000 Brugge See on map Region Vlaams Gewest Prov. West-Vlaanderen Arr. Brugge Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 FARAPULSE INC United States Net EU contribution € 1 780 000,00 Address 3715 haven avenue suite 110 94025 Menlo park See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 866 250,00 NEMOCNICE NA HOMOLCE Czechia Net EU contribution € 175 000,00 Address Roentgenova 2 15030 Praha 5 See on map Region Česko Praha Hlavní město Praha Activity type Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 DEUTSCHES HERZZENTRUM MUNCHEN Germany Net EU contribution € 245 750,00 Address Lazarettstrasse 36 80636 Munich See on map Region Bayern Oberbayern München, Kreisfreie Stadt Activity type Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00